Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Can biopsy be avoided in patients with clinical suspicion of prostate cancer and a negative result on multiparametric magnetic resonance imaging?

Baroni RH.

Radiol Bras. 2019 Sep-Oct;52(5):V-VI. doi: 10.1590/0100-3984.2019.52.5e1. No abstract available.

2.

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.

Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA.

J Urol. 2013 Nov;190(5):1721-1727. doi: 10.1016/j.juro.2013.05.052. Epub 2013 May 29.

3.

Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.

Bryk DJ, Llukani E, Huang WC, Lepor H.

J Urol. 2015 Nov;194(5):1234-40. doi: 10.1016/j.juro.2015.05.078. Epub 2015 May 21.

PMID:
26003206
4.

The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?

Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, Papotti M, Molineris I, Passera R, Regge D.

J Urol. 2014 Jul;192(1):60-6. doi: 10.1016/j.juro.2014.01.030. Epub 2014 Feb 8.

5.

The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Recabal P, Assel M, Sjoberg DD, Lee D, Laudone VP, Touijer K, Eastham JA, Vargas HA, Coleman J, Ehdaie B.

J Urol. 2016 Aug;196(2):374-81. doi: 10.1016/j.juro.2016.02.084. Epub 2016 Feb 23.

6.

Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.

Vourganti S, Rastinehad A, Yerram N, Nix J, Volkin D, Hoang A, Turkbey B, Gupta GN, Kruecker J, Linehan WM, Choyke PL, Wood BJ, Pinto PA.

J Urol. 2012 Dec;188(6):2152-2157. doi: 10.1016/j.juro.2012.08.025. Epub 2012 Oct 18.

7.

The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.

Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2016 May;195(5):1428-1435. doi: 10.1016/j.juro.2015.10.140. Epub 2015 Oct 31.

PMID:
26529298
8.

Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer.

Boesen L, Nørgaard N, Løgager V, Thomsen HS.

J Urol. 2017 Aug;198(2):310-315. doi: 10.1016/j.juro.2017.02.073. Epub 2017 Feb 21.

PMID:
28235549
9.

Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?

Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, Ashrafi AN, Cacciamani GE, Chen F, Duddalwar V, Stern MC, Ukimura O, Gill IS, Luis de Castro Abreu A.

J Urol. 2019 Feb;201(2):268-276. doi: 10.1016/j.juro.2018.08.046.

10.

Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.

Perlis N, Al-Kasab T, Ahmad A, Goldberg E, Fadak K, Sayyid R, Finelli A, Kulkarni G, Hamilton R, Zlotta A, Ghai S, Fleshner N.

J Urol. 2018 May;199(5):1182-1187. doi: 10.1016/j.juro.2017.11.074. Epub 2017 Nov 23. Erratum in: J Urol. 2018 Sep;200(3):660.

PMID:
29175542
11.

Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.

Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, Carrieri G, Rastinehad AR, Wiklund P, Tewari A.

Eur Urol Oncol. 2019 Sep 20. pii: S2588-9311(19)30141-5. doi: 10.1016/j.euo.2019.08.015. [Epub ahead of print]

PMID:
31548130
12.

High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.

Komai Y, Numao N, Yoshida S, Matsuoka Y, Nakanishi Y, Ishii C, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K.

J Urol. 2013 Sep;190(3):867-73. doi: 10.1016/j.juro.2013.03.078. Epub 2013 Mar 28.

PMID:
23542406
13.

Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.

Bryant RJ, Hobbs CP, Eyre KS, Davies LC, Sullivan ME, Shields W, Sooriakumaran P, Verrill CL, Gleeson FV, MacPherson RE, Hamdy FC, Brewster SF.

J Urol. 2019 Mar;201(3):510-519. doi: 10.1016/j.juro.2018.09.049.

PMID:
30266332
14.

Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.

Prendeville S, Gertner M, Maganti M, Pintilie M, Perlis N, Toi A, Evans AJ, Finelli A, van der Kwast TH, Ghai S.

J Urol. 2018 Jul;200(1):104-113. doi: 10.1016/j.juro.2018.01.081. Epub 2018 Feb 2.

PMID:
29408568
15.

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA.

J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.

PMID:
28373135
16.

Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.

Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, Marks LS.

J Urol. 2016 May;195(5):1421-1427. doi: 10.1016/j.juro.2015.11.055. Epub 2015 Dec 7.

17.

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.

Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM, Wijkstra H, Roobol MJ.

Eur Urol Oncol. 2018 Jun;1(2):109-117. doi: 10.1016/j.euo.2018.02.010. Epub 2018 May 15.

PMID:
31100233
18.

Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer.

Mortezavi A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, Hermanns T, Eberli D.

J Urol. 2018 Aug;200(2):309-318. doi: 10.1016/j.juro.2018.02.067. Epub 2018 Feb 21.

PMID:
29474846
19.

Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.

Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ.

Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.

PMID:
26651990
20.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078

Supplemental Content

Support Center